Hologic Unveils New Clinical Data Demonstrating AI-Powered Mammography's Accuracy in Breast Cancer Detection at EUSOBI Annual Meeting
Reuters
Sep 26, 2025
Hologic Unveils New Clinical Data Demonstrating AI-Powered Mammography's Accuracy in Breast Cancer Detection at EUSOBI Annual Meeting
Hologic Inc. has announced the presentation of new data on its AI-powered mammography technology at the European Society of Breast Imaging (EUSOBI) Annual Scientific Meeting in Aberdeen, Scotland. The studies evaluated the performance of Hologic's Genius AI® Detection 2.0 mammography solution, including its ability to associate AI scores from 3D mammography exams with tumor characteristics such as histologic grade and lymph node status. The research, conducted at Massachusetts General Hospital, analyzed approximately 600 biopsy-proven cancer cases. In addition to its AI-powered technologies, Hologic is also showcasing the next-generation Sentimag® Gen 3 device for tumor localization and breast cancer staging, developed by Endomag and recently launched in Europe. The results from these studies are being presented at EUSOBI and have not been published elsewhere.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hologic Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250926785023) on September 26, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.